Authors

  • Нигора Мирфозил кизи Асрарова

References

Bergstrom, D.J.; Kotb, R.; Louzada, M.L.; Sutherland, H.J.; Tavoularis, S.; Venner, C.P.; Côté, J.; LeBlanc, R.; Reiman, A.; Sebag, M.; et al. Consensus guidelines on the diagnosis of multiple myeloma and related disorders: Recommendations of the myeloma canada research network consensus guideline consortium. Clin. Lymphoma Myeloma Leuk. 2020, 20, e352–e367.

Raje, N.S.; Bhatta, S.; Terpos, E. Role of the RANK/RANKL pathway in multiple myeloma. Clin. Cancer Res. 2019, 25, 12–20.

Rajkumar, S.V.; Kumar, S. Multiple Myeloma: Diagnosis and Treatment. Mayo Clin. Proc. 2016, 91, 101–119.

The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br. J. Haematol. 2003, 121, 749–757.

Global Burden of Disease Cancer Collaboration; Fitzmaurice, C.; Abate, D.; Abbasi, N.; Abbastabar, H.; Abd–Allah, F.; Abdel–Rahman, O.; Abdelalim, A.; Abdoli, A.; Abdollahpour, I.; et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability–adjusted life–years for 29 cancer groups, 1990 to 2017: A systematic analysis for the global burden of disease study. JAMA Oncol. 2019, 5, 1749–1768.

Ho, M.; Patel, A.; Goh, C.Y.; Moscvin, M.; Zhang, L.; Bianchi, G. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Leukemia 2020, 34, 3111–3125.

Maes, A.; Menu, E.; Veirman, K.D.; Maes, K.; Vand Erkerken, K.; De Bruyne, E. The therapeutic potential of cell cycle targeting in multiple myeloma. Oncotarget 2017, 8, 90501–90520.

Kyle, R.A.; Durie, B.G.M.; Rajkumar, S.V.; Landgren, O.; Blade, J.; Merlini, G.; Kröger, N.; Einsele, H.; Vesole, D.H.; Dimopoulos, M.; et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010, 24, 1121–112

Kim, C.; Bhatta, S.; Cyprien, L.; Fonseca, R.; Hernandez, R.K. Incidence of skeletal–related events among multiple myeloma patients in the United States at oncology clinics: Observations from real–world data. J. Bone Oncol. 2018, 14, 100215.

Costa, L.J.; Brill, I.K.; Omel, J.; Godby, K.; Kumar, S.K.; Brown, E.E. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv. 2017, 1, 282–287.

Landgren, O.; Kyle, R.A.; Pfeiffer, R.M.; Katzmann, J.A.; Caporaso, N.E.; Hayes, R.B.; Dispenzieri, A.; Kumar, S.; Clark, R.J.; Baris, D.; et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study. Blood 2009, 113, 5412–5417.

Mikhael, J.; Ismaila, N.; Cheung, M.C.; Costello, C.; Dhodapkar, M.V.; Kumar, S.; Lacy, M.; Lipe, B.; Little, R.F.; Nikonova, A.; et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J. Clin. Oncol. 2019, 37, 1228–1263.